RxDoctor Payments Data

Shweta Sharan, MD

Family Medicine · Monroe, LANPI 1467641746

Payments from drug & device makers

$919in general payments, 2019–2025

Across 22 payments — averaging $41.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$628
  • Amgen$104
  • AstraZeneca$67
  • Johnson & Johnson$33
  • Exact Sciences$32
  • Pfizer$24
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$628
Amgen1$104
AstraZeneca1$67
Johnson & Johnson2$33
Exact Sciences2$32
Pfizer1$24
Merck1$17
Bayer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$919 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,908
Medicare patients
165
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$173,494
FarxigaDapagliflozin Propanediol67$61,262
JardianceEmpagliflozin44$60,943
EliquisApixaban53$51,338
MounjaroTirzepatide31$35,022
RybelsusSemaglutide21$34,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$34,310
Spiriva HandihalerTiotropium Bromide40$33,451
TradjentaLinagliptin20$28,986
EntrestoSacubitril/Valsartan14$25,034
LinzessLinaclotide34$23,984
TrulicityDulaglutide17$16,006
JanuviaSitagliptin Phosphate16$12,104
MitigareColchicine18$9,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$8,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$628$209,947162 claims
AstraZenecaFarxiga, Symbicort$67$68,24984 claims
PfizerEliquis$24$51,33853 claims
MerckJanuvia$17$12,10416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →